Taken consistently, PrEP is close to completely effective at preventing HIV through sex. The figures commonly quoted from clinical trials, often around eighty-six per cent, measured something different: the effect across everyone randomised, including those who did not take the tablets. Among people with drug levels showing consistent use, protection approaches complete.
What did the main trials show?
The UK PROUD study and the French IPERGAY study both reported around an eighty-six per cent reduction in HIV infections among gay and bisexual men, using daily and event-based dosing respectively. Both figures were calculated across all participants regardless of whether they took the medication. Analyses looking at drug levels in participants who acquired HIV consistently found little or no drug present, which is the finding that matters.
How does that compare with other prevention?
Condoms are highly effective when used correctly and consistently, and their real-world effectiveness is reduced by inconsistent use, breakage and slippage in much the same way. PrEP has the practical advantage that it does not depend on a decision made during sex, which is why it has changed infection rates in populations where condom promotion alone had stalled.
How many doses a week are enough?
For anal sex, studies indicate high protection at four or more doses a week, with protection increasing as adherence rises towards daily. This reflects how tenofovir accumulates in rectal tissue. It is not an invitation to aim for four, since dosing patterns drift downwards rather than upwards, but it does explain why an occasional missed day does not undo protection.
Have there been failures?
A very small number of cases worldwide have been documented in people with confirmed good adherence, nearly all involving strains resistant to the drugs used. These are rare enough to be reported individually in the medical literature, which itself indicates how uncommon they are. The overwhelming majority of infections in people prescribed PrEP occur where drug levels show it was not being taken.
What reduces effectiveness in practice?
Starting sex before the loading period is complete. Stopping too soon after the last exposure. Gaps caused by a missed appointment or running out of supply. Using the event-based schedule for types of sex where it is not established. Acquiring HIV before starting, which is why an HIV test precedes the first prescription.
Does it work for everyone?
The evidence for anal sex in cisgender men is the strongest, and event-based dosing is only recommended in that context. Daily PrEP is effective for vaginal and frontal sex, but requires a longer loading period and less tolerance of missed doses, because those tissues accumulate drug more slowly. Evidence in trans people using gender-affirming hormones indicates PrEP works and hormones do not interfere.
What it does not do
PrEP has no effect on gonorrhoea, chlamydia, syphilis, herpes, hepatitis C or mpox. Three-monthly screening exists alongside it for that reason, and it is part of the prescription rather than an optional extra.
The realistic summary
If you take it as directed, allow the loading period and continue for the recommended time after your last exposure, HIV is effectively off the table. The variability in published figures is a story about human behaviour rather than about the drug.